Quantcast

North Bay Business Journal

Thursday, May 9, 2013, 4:10 pm

BioMarin loss widens as R&D costs increase

Print Friendly Print Friendly    

Share this item

    SAN RAFAEL — BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) recently reported a net loss of $39.8 million, or 31 cents per share, for the first quarter ended March 31, compared to a net loss of $24 million in the same period last year.

    BioMarin, a developer of drugs to treat rare disorders, said the first-quarter loss was the result of an increase in research and development costs that offset an increase in net product revenue. R&D spending in the first quarter this year reached $83.7 million, compared to $73.8 million in the same period last year.

    Administration and sales costs also increased to $51 million in the first quarter, compared to $45 million last year.

    As of March 31, BioMarin said it had cash, cash equivalents and short and long-term investments totaling $525.7 million, compared to $566.7 million on December 31, 2012.

    “In the first quarter, we continued to execute on our development goals as we head into another potentially transformative year for the company,” Jean-Jacques Bienaimé, chief executive officer of BioMarin, said in a statement. ”We made good progress on a number of important fronts including commercial, R&D, regulatory and business development.”

    BioMarin currently lists seven drugs in its pipeline that will reach key phases in 2013.

    The company projects 2013 total revenue to range between $530 million and $555 million.

    Shares of BioMarin at the end of today were $66.41, up roughly 1.7 percent, but in after-hours trading slid back down to $66.18.

    Copyright © 1988–2014 North Bay Business Journal
    View the policy for linking to website content.

    Print Friendly Print Friendly    

    Submit Your Comments

    Required

    Required, will not be published

    Comments are moderated and generally will be posted if they are on-topic and not abusive. For more information, please see our Comments and Letters Policy. To share this item by email or social media, use the links above.

    Do not use this form to contact people, companies or organizations mentioned in this story. Contact them directly. Private messages left here will be deleted.